SLAS Discovery

Scope & Guideline

Exploring New Horizons in Molecular Medicine

Introduction

Immerse yourself in the scholarly insights of SLAS Discovery with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2472-5552
PublisherELSEVIER SCIENCE INC
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2017 to 2024
AbbreviationSLAS DISCOV / SLAS Discov.
Frequency10 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

SLAS Discovery focuses on innovative methodologies and technologies that drive drug discovery and development, particularly emphasizing high-throughput screening (HTS) and its applications across various therapeutic areas.
  1. High-Throughput Screening (HTS):
    The journal extensively covers the development and optimization of high-throughput screening methodologies for drug discovery, enabling rapid evaluation of large compound libraries against biological targets.
  2. Cell-Based Assays and Imaging:
    SLAS Discovery emphasizes the use of cell-based assays, including high-content imaging and 3D cell cultures, to better mimic in vivo conditions and enhance the relevance of screening results.
  3. Target Identification and Validation:
    Research published in the journal often focuses on novel strategies for target identification and validation, including the application of proteomics and genomics to discover new drug targets.
  4. Automation and Robotics in Drug Discovery:
    The journal highlights advancements in automation and robotics that facilitate efficient assay development and compound screening, improving reproducibility and data quality in drug discovery.
  5. Phenotypic Screening:
    SLAS Discovery also explores phenotypic screening approaches that assess biological responses to compounds in cellular models, offering insights into complex drug action mechanisms.
  6. Emerging Technologies:
    The journal is dedicated to showcasing emerging technologies such as artificial intelligence (AI) and machine learning (ML) in drug discovery, aiming to enhance data analysis and predictive capabilities.
The landscape of drug discovery is rapidly changing, and SLAS Discovery reflects this evolution through an increasing focus on several key emerging themes.
  1. COVID-19 Therapeutics:
    A significant number of recent publications are dedicated to discovering and validating therapeutics for COVID-19, reflecting the urgent need for effective treatments and the journal's responsiveness to global health challenges.
  2. 3D Cell Culture and Organoids:
    There is a growing trend towards the use of 3D cell culture systems and organoids, which provide more accurate representations of human tissues, enhancing drug screening and development processes.
  3. Artificial Intelligence and Machine Learning:
    The integration of AI and machine learning techniques into drug discovery processes is on the rise, with studies focusing on data mining, predictive modeling, and automated analysis to streamline hit identification.
  4. Targeted Protein Degradation:
    Research on targeted protein degradation, particularly using PROTACs (Proteolysis Targeting Chimeras), is emerging as a significant area of interest, offering new strategies for drug discovery against challenging targets.
  5. Synergistic Drug Combinations:
    There is an increasing focus on identifying synergistic drug combinations to enhance therapeutic efficacy, particularly in cancer treatment, which reflects a shift towards personalized medicine approaches.

Declining or Waning

While SLAS Discovery continues to evolve, certain themes are becoming less prominent in recent publications, indicating a shift in focus within the field.
  1. Traditional Biochemical Assays:
    There is a noticeable decline in publications focusing solely on traditional biochemical assays, as the field moves towards more complex and physiologically relevant models.
  2. Single-Dimensional Drug Screening:
    Research centered around single-dimensional drug screening methods is waning, with a shift towards more integrated and multi-parametric approaches that provide a broader understanding of drug effects.
  3. Basic Pharmacology Studies:
    Basic pharmacology studies that do not incorporate advanced technologies or high-throughput capabilities appear to be less frequent, as there is a growing emphasis on translational research and clinical relevance.
  4. In Vitro Models Lacking Complexity:
    The use of simplistic in vitro models is decreasing, as researchers prioritize more complex systems that better replicate human physiology, such as organoids and multi-cellular models.
  5. Focus on Established Targets:
    There is a reduction in studies targeting well-characterized pathways or proteins, as the field increasingly seeks novel targets and mechanisms of action to overcome drug resistance.

Similar Journals

Current Bioinformatics

Innovating Computational Techniques for Biological Insights
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1574-8936Frequency: 6 issues/year

Current Bioinformatics, an esteemed journal published by Bentham Science Publishers Ltd, serves as a pivotal platform for the dissemination of cutting-edge research in the fields of bioinformatics, biochemistry, computational mathematics, genetics, and molecular biology. With an ISSN of 1574-8936 and an E-ISSN of 2212-392X, this journal has established itself as a vital resource for researchers, professionals, and students keen on exploring interdisciplinary approaches to biological data analysis. Its prominence is reflected in its quartile rankings for 2023, where it stands in Q3 for biochemistry and computational mathematics, alongside Q4 rankings in genetics and molecular biology. Current Bioinformatics, located in the United Arab Emirates and converging from 2007 to 2024, aims to foster innovation in the field by presenting original research articles, reviews, and case studies that drive forward our understanding of complex biological systems through computational techniques. This journal is an integral resource for those wishing to stay at the forefront of bioinformatics research and applications.

MOLECULAR & CELLULAR PROTEOMICS

Elevating the discourse in molecular and cellular proteomics.
Publisher: ELSEVIERISSN: Frequency: 1 issue/year

MOLECULAR & CELLULAR PROTEOMICS, published by Elsevier, stands as a premier journal in the fields of Biochemistry, Analytical Chemistry, and Molecular Biology, with a distinguished Q1 ranking reflecting its high impact and contribution to the scientific community. Established in 2002, this journal has consistently provided a platform for the latest research in protein science, merging molecular biology with advanced analytical techniques. With impressive Scopus rankings—41st in Biochemistry and 16th in Analytical Chemistry—it caters to an audience of researchers, professionals, and students eager to explore cutting-edge developments in proteomics. Although currently not designated as open access, the journal aims to foster knowledge dissemination through accessible research content. As it continues to evolve until 2024, MOLECULAR & CELLULAR PROTEOMICS is essential for anyone passionately engaged in the ever-expanding field of proteomics.

Drug Metabolism and Pharmacokinetics

Shaping the Future of Therapeutics Through Metabolism Insights
Publisher: JAPANESE SOC STUDY XENOBIOTICSISSN: 1347-4367Frequency: 6 issues/year

Drug Metabolism and Pharmacokinetics is a premier academic journal committed to advancing the understanding of drug metabolism processes and pharmacokinetic principles critical to the development of therapeutics. Published by the Japanese Society for the Study of Xenobiotics, this journal has established itself as a vital resource within Pharmaceutical Science and Pharmacology, achieving a respectable Q2 ranking in the latest 2023 metrics. Spanning from 2002 to 2024, the journal publishes original research articles, reviews, and insights that address contemporary issues in xenobiotic metabolism and pharmacologic practices. With its ISSN of 1347-4367 and E-ISSN of 1880-0920, Drug Metabolism and Pharmacokinetics is indexed in leading databases, enhancing its visibility and accessibility for researchers, professionals, and students alike. By fostering a rigorous scientific dialogue, the journal plays an essential role in shaping the future of pharmacology and pharmaceutical sciences.

ChemMedChem

Bridging fundamental science and practical medicine.
Publisher: WILEY-V C H VERLAG GMBHISSN: 1860-7179Frequency: 24 issues/year

ChemMedChem is a leading international journal published by WILEY-V C H VERLAG GMBH in the United Kingdom, specializing in the interdisciplinary fields of medicinal chemistry and drug discovery. With a commendable impact factor that places it in the Q1 quartile for Organic Chemistry and among the Q2 ranks in several other key categories including Biochemistry, Molecular Medicine, and Pharmacology, ChemMedChem serves as a vital platform for the dissemination of innovative research and transformative insights in the development of pharmaceutical agents. Since its inception in 2006, this journal has been at the forefront of advancing knowledge that bridges the gap between fundamental research and practical applications in medicine, making it an essential resource for researchers, professionals, and students alike. Although it currently does not offer Open Access options, the journal ensures high-quality peer-reviewed content that engages its audience and fosters collaborative scientific discourse.

CURRENT DRUG TARGETS

Illuminating Pathways in Clinical Biochemistry
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-4501Frequency: 16 issues/year

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

JOURNAL OF CELLULAR BIOCHEMISTRY

Elevating Biochemical Insights for Tomorrow's Science
Publisher: WILEYISSN: 0730-2312Frequency: 12 issues/year

Journal of Cellular Biochemistry is a premier academic journal dedicated to advancing the field of biochemistry and cellular biology. Published by Wiley, this influential journal has a significant impact factor that underscores its relevance and authority within the scientific community. With its ISSN 0730-2312 and E-ISSN 1097-4644, the journal has been on the frontier of research since its inception in 1982, and is expected to continue publishing cutting-edge studies through 2024. As evidenced by its ranking in the 2023 Scopus Quartiles, it holds a rank of Q2 in Biochemistry and Q3 in both Cell and Molecular Biology, placing it among the top tiers of scientific journals in these disciplines. The Journal of Cellular Biochemistry serves as a vital resource for researchers, professionals, and students alike, providing a platform for the dissemination of innovative ideas and findings that shape our understanding of cellular processes and biochemical pathways. Though it does not currently offer Open Access options, its robust peer-review process ensures that each publication meets the highest academic standards, thus solidifying its esteemed position in the landscape of biochemical research.

NATURAL PRODUCT RESEARCH

Exploring the Essence of Nature's Compounds
Publisher: TAYLOR & FRANCIS LTDISSN: 1478-6419Frequency: 24 issues/year

NATURAL PRODUCT RESEARCH is a distinguished journal published by Taylor & Francis Ltd, dedicated to advancing the field of natural product science through the dissemination of high-quality research. Established in 2003, this journal serves as a pivotal platform for scholars in Analytical Chemistry, Biochemistry, Organic Chemistry, and Plant Science, boasting an impressive categorization including Q2 in Plant Science and Q3 in the other disciplines for 2023. With a current Scopus ranking that highlights its significance within various scientific communities, NATURAL PRODUCT RESEARCH reflects the complexities and innovations associated with natural compounds and their applications. Researchers, professionals, and students will find valuable insights and breakthroughs that contribute to the understanding of bioactive compounds and their roles in health and environmental sustainability. Access options are available, ensuring that the latest findings are accessible to a global audience. As this journal continues to publish until 2024, it remains an essential resource for those at the forefront of natural product research.

JOURNAL OF BIOLOGICAL CHEMISTRY

Exploring the Intersections of Biochemistry and Cell Biology
Publisher: ELSEVIERISSN: Frequency: 1 issue/year

JOURNAL OF BIOLOGICAL CHEMISTRY, published by Elsevier, is a premier interdisciplinary journal dedicated to advancing our understanding of biochemistry, cell biology, and molecular biology. With a prestigious history dating back to 1945 and an impressive convergence of research expected to continue through 2024, this journal holds a Q1 ranking in all three of its core categories, signaling its critical influence in the respective fields, supported by a robust Scopus ranking that places it among the top echelons of internationally recognized research. Although currently not available as Open Access, the journal is essential for researchers and professionals looking to stay abreast of the latest breakthroughs and innovations in biochemical research. With a deep commitment to scientific rigor and a focus on diverse topics ranging from cellular processes to molecular mechanisms, the Journal of Biological Chemistry serves as a vital resource for the academic community, shaping the future of biological sciences.

EXPERT OPINION ON THERAPEUTIC TARGETS

Advancing therapeutic innovation through expert insights.
Publisher: TAYLOR & FRANCIS LTDISSN: 1472-8222Frequency: 12 issues/year

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Unraveling the Complexities of Molecular Interactions
Publisher: TAYLOR & FRANCIS INCISSN: 0739-1102Frequency: 18 issues/year

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, published by TAYLOR & FRANCIS INC, serves as a pivotal platform for the dissemination of original research in the fields of biochemistry, molecular biology, and structural biology. With an ISSN of 0739-1102 and an E-ISSN of 1538-0254, this esteemed journal has garnered attention for its rigorous peer-review process and commitment to high-quality scientific inquiry since its inception in 1981. Ranking in the Q2 quartile for miscellaneous medicine and the Q3 quartile for both molecular and structural biology, it consistently demonstrates a significant impact within its specialties, evidenced by a high Scopus ranking. Researchers, professionals, and students are encouraged to engage with cutting-edge studies addressing the complex interactions and dynamics of biomolecules, making this journal a vital resource for advancing knowledge in the biological sciences. Although it does not offer open access options, its valuable contributions are vital for the ongoing discourse within the scientific community.